PE20240051A1 - Metodos para el tratamiento del cancer con administracion subcutanea de anticuerpos anti-pd1 - Google Patents

Metodos para el tratamiento del cancer con administracion subcutanea de anticuerpos anti-pd1

Info

Publication number
PE20240051A1
PE20240051A1 PE2023002821A PE2023002821A PE20240051A1 PE 20240051 A1 PE20240051 A1 PE 20240051A1 PE 2023002821 A PE2023002821 A PE 2023002821A PE 2023002821 A PE2023002821 A PE 2023002821A PE 20240051 A1 PE20240051 A1 PE 20240051A1
Authority
PE
Peru
Prior art keywords
cancer
subcutaneous administration
pembrolizumab
antibodies
treatment
Prior art date
Application number
PE2023002821A
Other languages
English (en)
Spanish (es)
Inventor
Mallika Lala
Miranda Silva Carolina De
Ferdous Gheyas
Yogita Krishnamachari
Elliot Keith Chartash
Lokesh Jain
Venkata Naga Ratna Pavan Kumar Vaddady
Original Assignee
Merck Sharp And Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp And Dohme Llc filed Critical Merck Sharp And Dohme Llc
Publication of PE20240051A1 publication Critical patent/PE20240051A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2023002821A 2021-04-08 2022-04-04 Metodos para el tratamiento del cancer con administracion subcutanea de anticuerpos anti-pd1 PE20240051A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163172299P 2021-04-08 2021-04-08
PCT/US2022/023250 WO2022216580A1 (en) 2021-04-08 2022-04-04 Methods for treating cancer with subcutaneous administration of anti-pd1 antibodies

Publications (1)

Publication Number Publication Date
PE20240051A1 true PE20240051A1 (es) 2024-01-09

Family

ID=83546458

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023002821A PE20240051A1 (es) 2021-04-08 2022-04-04 Metodos para el tratamiento del cancer con administracion subcutanea de anticuerpos anti-pd1

Country Status (21)

Country Link
US (1) US20250074983A1 (cg-RX-API-DMAC7.html)
EP (1) EP4320163A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024513247A (cg-RX-API-DMAC7.html)
KR (1) KR20230170029A (cg-RX-API-DMAC7.html)
CN (1) CN117279952A (cg-RX-API-DMAC7.html)
AR (1) AR125296A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022254960A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023020867A2 (cg-RX-API-DMAC7.html)
CA (1) CA3214617A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023002976A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023013273A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230473A (cg-RX-API-DMAC7.html)
DO (2) DOP2023000216A (cg-RX-API-DMAC7.html)
EC (1) ECSP23076276A (cg-RX-API-DMAC7.html)
GE (1) GEAP202416385A (cg-RX-API-DMAC7.html)
IL (1) IL307430A (cg-RX-API-DMAC7.html)
JO (1) JOP20230243A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023011857A (cg-RX-API-DMAC7.html)
PE (1) PE20240051A1 (cg-RX-API-DMAC7.html)
TW (1) TW202305009A (cg-RX-API-DMAC7.html)
WO (1) WO2022216580A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112203642B (zh) 2019-03-25 2025-03-07 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
WO2025140467A1 (zh) * 2023-12-29 2025-07-03 上海复宏汉霖生物技术股份有限公司 稳定的高浓度抗pd-1抗体药物制剂
WO2026124472A1 (zh) * 2024-12-10 2026-06-18 四川科伦博泰生物医药股份有限公司 治疗组合及其用途和治疗方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP2330213A1 (en) 2003-03-05 2011-06-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
WO2014165422A1 (en) 2013-04-02 2014-10-09 Merck Sharp & Dohme Corp. Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3634484A4 (en) * 2017-06-05 2022-01-12 The Council of the Queensland Institute of Medical Research A COMBINATION OF OR A BI-SPECIFIC BINDING MOLECULE TO AN IMMUNOCONTROL MOLECULE ANTAGONIST AND A RANK-L (NF-κB-LIGAND) ANTAGONIST FOR CANCER THERAPY OR PROPHYLAXIS AND USES THEREOF
CN119792515A (zh) * 2018-02-13 2025-04-11 默沙东有限责任公司 用抗pd-1抗体和抗ctla-4抗体治疗癌症的方法
MX2020009824A (es) 2018-07-25 2021-01-15 Alteogen Inc Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma.
US20210380694A1 (en) * 2018-11-07 2021-12-09 Merck Sharp & Dohme Corp. Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
CN112203642B (zh) * 2019-03-25 2025-03-07 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物

Also Published As

Publication number Publication date
DOP2026000117A (es) 2026-07-31
ECSP23076276A (es) 2023-11-30
EP4320163A1 (en) 2024-02-14
TW202305009A (zh) 2023-02-01
CA3214617A1 (en) 2022-10-13
WO2022216580A1 (en) 2022-10-13
MX2023011857A (es) 2023-10-19
CO2023013273A2 (es) 2023-10-30
GEAP202416385A (en) 2024-02-26
IL307430A (en) 2023-12-01
JP2024513247A (ja) 2024-03-22
AU2022254960A1 (en) 2023-11-23
EP4320163A4 (en) 2025-03-05
JOP20230243A1 (ar) 2023-10-08
CN117279952A (zh) 2023-12-22
CL2023002976A1 (es) 2024-06-28
US20250074983A1 (en) 2025-03-06
KR20230170029A (ko) 2023-12-18
AU2022254960A9 (en) 2023-11-30
DOP2023000216A (es) 2023-11-30
BR112023020867A2 (pt) 2023-12-12
AR125296A1 (es) 2023-07-05
CR20230473A (es) 2023-11-30

Similar Documents

Publication Publication Date Title
MX2023002024A (es) Métodos de tratamiento con modulador de miosina.
MX2023013738A (es) Analogos de la camptotecina, conjugados y metodos de uso.
AR078224A1 (es) Composicon para el tratamiento del cancer de prostata
MX2017011280A (es) Terapia neuro-afectiva regional topica con cannabinoides.
PE20221338A1 (es) Metodos de tratamiento del cancer de pulmon de celulas pequenas con formulaciones de lurbinectedina
MA56827A1 (fr) Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine
MX2022000430A (es) Administracion de agonista de sting e inhibidores de puntos de control.
CO2021016606A2 (es) Métodos para administrar un anticuerpo anti-cd38 para tratar el mieloma múltiple
MX2024005237A (es) Compuesto que tiene actividad de degradacion de la proteina btk, y usos medicos del mismo.
CL2022002503A1 (es) Composición farmacéutica para el tratamiento de cáncer que comprende proteína de fusión que se compone
ECSP23076276A (es) Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1
MX2022012354A (es) Metodos de administracion de una preparacion inyectable de aripiprazol.
CL2024000397A1 (es) Administración de agentes terapéuticos por vía venosa coronaria retrógrada o sinusal
MX2024001050A (es) Métodos de tratamiento de la enfermedad de parkinson y/o de la enfermedad o trastorno(s) de los cuerpos de lewy.
MX2025015101A (es) Un metodo para el tratamiento de tumores solidos con un conjugado anticuerpo-farmaco dirigido a claudina 18.2
AR131503A1 (es) Antagonistas de hpk1 espirocíclicos y usos de los mismos
JP2021130679A (ja) 造血幹細胞移植患者の処置
MX2022011539A (es) Metodo de produccion de una composicion de suero para la prevencion o el tratamiento de enfermedades infecciosas relacionadas con las mucosas en mamiferos jovenes, composicion de suero producida de este modo y uso de la misma.
Malik Standardization of propofol and ketamine for constant rate infusion and their comparative evaluation with halothane anaesthesia in buffaloes
Cho et al. Anaphylaxis induced by priming dose of rocuronium during induction of anesthesia: Report of two cases
CR20220040A (es) Régimen de dosificación y administración para el tratamiento o prevención de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab
UA144832U (uk) Спосіб комбінованого лікування аутизму
RU2774030C1 (ru) Способ ускорения процесса постлучевого восстановления селезенки лабораторных животных
UA144830U (uk) Спосіб комбінованого лікування дитячого церебрального паралічу
AR130444A1 (es) Métodos para el tratamiento de infecciones virales